-
1 Comment
Amyris, Inc is currently in a long term uptrend where the price is trading 40.5% above its 200 day moving average.
From a valuation standpoint, the stock is 113.5% more expensive than other stocks from the Basic Materials sector with a price to sales ratio of 21.0.
Amyris, Inc's total revenue rose by 96.7% to $80M since the same quarter in the previous year.
Its net income has dropped by 39.0% to $-110M since the same quarter in the previous year.
Finally, its free cash flow grew by 72.4% to $-13M since the same quarter in the previous year.
Based on the above factors, Amyris, Inc gets an overall score of 3/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US03236M2008 |
Sector | Basic Materials |
Industry | Specialty Chemicals |
PE Ratio | None |
---|---|
Target Price | 1 |
Market Cap | 18M |
Beta | 1.19 |
Dividend Yield | 0.0% |
Amyris, Inc. operates as a biotechnology company in Europe, North America, Asia, South America, and internationally. It creates, manufactures, and commercializes consumer products and ingredient, including clean beauty, personal care, and health and wellness consumer products; and ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. The company markets its products under the Biossance, JVN, Rose Inc., Pipette, Costa Brazil, OLIKA, Purecane, Terasana, MenoLabs, EcoFabulous, Stripes, and 4U by Tia brand names. It has a collaboration and license agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California. On August 9, 2023, Amyris, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for AMRS using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025